Accession Number:

AD1118396

Title:

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Descriptive Note:

Journal Article - Open Access

Corporate Author:

NEBRASKA UNIV MEDICAL CENTER OMAHA OMAHA United States

Report Date:

2020-12-11

Pagination or Media Count:

13.0

Abstract:

Severe coronavirus disease 2019 Covid-19 is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known. We conducted a double-blind, randomized, placebo-controlled trial evaluating baricitinib plus remdesivir in hospitalized adults with Covid-19. All the patients received remdesivir 10 days and either baricitinib 14 days or placebo control.The primary outcome was the time to recovery. The key secondary outcome was clinical status at day 15.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE